+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: a matched cohort analysis

Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: a matched cohort analysis

World Journal of Urology 31(6): 1511-1517

To compare the biochemical outcomes reported after radical prostatectomy (RP) versus high dose permanent prostate brachytherapy (HDPPB) using iodine-125 seeds in the treatment of matched high risk prostate cancer (HiPCa). In this retrospective review, 55 HiPCa patients treated between March 2006 and August 2011, who underwent HDPPB using iodine-125 seeds combined with external beam radiation therapy (EBRT) or androgen deprivation therapy (ADT), were compared with 55 HiPCa patients who underwent RP. Patients were matched for age, prostate-specific antigen (PSA), clinical stage, and Gleason scores. The biochemical outcomes after HDPPB and RP were compared via Kaplan-Meier analysis. Of the 110 patients analyzed, the mean ages, PSA, and Gleason biopsy scores were similar between the two cohorts. Among patients who underwent HDPPB, 20 patients (36.4%) had received adjuvant EBRT. Of this subsample, most patients (98.2%) had received adjuvant ADT for 3 months. Among patients with RP, 20 patients (36.4%) had received adjuvant EBRT, whereas 28 patients had received adjuvant ADT. The mean implanted seed numbers were 92.8, the mean D90 was 218.7 Gy, and the mean V100 was 96.1% after HDPPB. With regard to oncological outcomes, biochemical disease-free survival rates were similar between the two cohorts (82.6 vs. 81.1%, p = 0.982). Urethrorectal fistula developed in one patient with HDPPB. RP and HDPPB, using iodine-125 seeds with combined treatment modalities, exhibited similar biochemical recurrence-free survival rates among HiPCa patients. Further prospective studies with greater sample sizes and longer follow-up periods are needed to validate these results.

(PDF emailed within 0-6 h: $19.90)

Accession: 036869100

Download citation: RISBibTeXText

PMID: 23624718

DOI: 10.1007/s00345-013-1086-3

Related references

Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy. American Journal of Clinical Oncology 29(5): 451-457, 2006

High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse. Bju International 110 Suppl 4: 71-76, 2013

Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. European Urology 2018, 2018

A Matched Comparison of High-Risk Prostate Cancer Patients Treated With Dose-Escalated, Image Guided Adaptive External Beam Radiation Therapy (EBRT) Versus Pelvic EBRT Plus High-Dose-Rate Brachytherapy Boost. International Journal of Radiation Oncology*biology*physics 93(3): S121-S122, 2015

Dose-escalated Adaptive Image Guided Radiation Therapy Versus High-dose-rate Brachytherapy Monotherapy for Gleason 7 Intermediate-Risk Prostate Cancer: A Matched Pair Analysis. International Journal of Radiation Oncology*biology*physics 84(3): S369-S370, 2012

Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?. International Journal of Clinical Oncology 23(4): 757-764, 2018

Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. Bju International 96(1): 43-47, 2005

An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. Journal of Urology 177(6): 2151-6; Discussion 2156, 2007

Prospective Cohort of Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Analysis of Patient Satisfaction and Interference with Daily Activities between 125-iodine, 103-palladium and 131-cesium. BrachyTherapy 15: S201-S202, 2016

Cost Effectiveness of Prostate Boost with High-Dose Rate Brachytherapy Versus Intensity Modulated Radiation Therapy in the Treatment of Intermediate-High Risk Prostate Cancer. International Journal of Radiation Oncology*biology*physics 99(2): S37-S38, 2017

Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer. BrachyTherapy 17(6): 852-857, 2018

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 73(2): 341-346, 2008

Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis. Advances in Radiation Oncology 3(2): 190-196, 2018

Permanent Prostate Brachytherapy for Organ Confined High-Risk Prostate Cancer Patients. BrachyTherapy 12: S65-S66, 2013

Evaluation of health-related quality of life in patients with prostate cancer after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy. Urologia Internationalis 85(2): 173-179, 2011